g55

Doxycycline is an orally active tetracycline antibiotic with broad-spectrum inhibitory effects on matrix metalloproteinases (MMPs), possessing both antibacterial and antitumor activities, and is commonly used in inducible gene expression ON-OFF systems.

Doxycycline (hyclate) is an orally active tetracycline antibiotic with broad-spectrum inhibitory activity against matrix metalloproteinases (MMPs), possessing both antibacterial and antitumor properties, and is commonly used in inducible gene expression ON-OFF systems.

Doxycycline hydrochloride (Hyclate) is an orally active tetracycline antibiotic with broad-spectrum matrix metalloproteinase (MMP) inhibitory activity, possessing both antibacterial and anti-cancer cell proliferation effects, and can be used to induce gene expression in ON-OFF systems.

ISAM-CG557 is a selective CB2R agonist with a Ki of 54.6 nM. It reduces intracellular ROS levels and caspase activity, demonstrating significant MAPK bias and moderate G-protein bias, with CB2REC50 values of 0.60 nM for cAMP, 60.9 nM for β-arrestin, and 0.03 nM for MAPK. ISAM-CG557 exerts potent anti-inflammatory effects by decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokines in cells. It is utilized in the study of neuroinflammation and neurodegenerative diseases.

DPPE-PEG550 serves as a PEG lipid functional terminal group used for synthesizing liposomes (LPs) to design conjugated polymer nanoparticles. Liposome nanoparticles (LNPs) are capable of further coupling with other biomolecules through biotin modification and carboxyl terminals. Functionalized nanoparticles can target specific cell proteins for labeling purposes. Using streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles can bind with biotinylated antibodies on cell surface receptors, enabling applications in fluorescence-based imaging and sensing.

18:0 mPEG550 PE (ammonium) is designed for synthesizing liposomes (LPs) with PEG lipid functional end groups, facilitating the creation of conjugated polymer nanoparticles. The liposomal nanoparticles (LNPs), modified with biotin and carboxyl ends, can further couple with various biomolecules. These functionalized nanoparticles are applicable in targeting specific cellular proteins. By utilizing streptavidin as a linker, the biotinylated PEG lipid-conjugated polymer nanoparticles can bind to biotinylated antibodies on cell surface receptors, enabling applications in fluorescence-based imaging and sensing.

DMPE-PEG550 is a PEG lipid with functional end groups designed for the synthesis of liposomes (LPs) and the creation of conjugated polymer nanoparticles. Liposome nanoparticles (LNPs) feature biotin modifications and carboxyl ends, allowing further coupling with other biomolecules. These functional nanoparticles are employed for targeted labeling of specific cell proteins. Using streptavidin as a linker, the biotinylated PEG lipid conjugate polymer nanoparticles can bind to biotinylated antibodies on cell surface receptors, enabling applications in fluorescence-based imaging and sensing.

18:1 PEG550 PE is utilized as a PEG lipid functional end group for synthesizing liposomes (LPs) and designing conjugated polymer nanoparticles. Liposome nanoparticles (LNPs), featuring biotin modifications and carboxyl terminals, facilitate further coupling with other biomolecules. These functionalized nanoparticles are employed for targeted labeling of specific cellular proteins. Utilizing streptavidin as a linker, biotinylated PEG lipid-conjugated polymer nanoparticles can bind to biotinylated antibodies on cell surface receptors, enabling fluorescence-based imaging and sensing applications.

G-5555 is a potent inhibitor of p21-activated kinase 1 (PAK1) (Kis: 3.7 nM and 11 nM for PAK1 and PAK2, respectively).

VRT-532 (CFpot-532) is an effective modulator of CFTR and is commonly used in studies of cystic fibrosis (CF) caused by CFTR defects. Modification of CFTR by this small molecule modulator can increase arylsulfatase B (ARSB), which is necessary to reduce the accumulation of sulphate glycosaminosaccharide (gag), thus reducing the accumulation of 4-chondroitin sulfate in cystic fibrosis.

Gatifloxacin (CG5501) is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

Ivacaftor (VX-770) (VX-770) is a potentiator of CFTR targeting G551D-CFTR (EC50: 100 nM) and F508del-CFTR (EC50: 25 nM) in Fisher rat thyroid cells, respectively.

PG01 is a potent CFTR Cl-channel potentiator, effective against ΔF508 (Ka 0.3 μM), and also against E193K, G970R and G551D (CFTR mutants), with Kd values of 0.22 μM, 0.45 μM and 1.94 μM, respectively.PG01 increases ΔF508-CFTR Cl- currents upon addition of forskolin. F508-CFTR Cl-current upon addition of Forskolin, correcting the gating defect of CFTR mutants.

GLPG1837 (ABBV-974) is an effective CFTR potentiator, with EC50s of 3 nM and 339 nM for F508del and G551D CFTR, respectively.

G-5555 hydrochloride is a potent and selective p21-activated kinase 1 (PAK1) inhibitor with a Ki of 3.7 nM.

AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.

SG-55 is a selective, non-competitive, orally active inhibitor of AKR1C3, with an IC50 of 5 nM and a Ki of 10 nM. It has over 2000-fold higher selectivity for AKR1C3 compared to AKR1C1, AKR1C2, and AKR1C4 (>10 μM). SG-55 enhances the NADPH/NADP+ ratio, decreases the GSH/GSSG ratio, and induces DNA double-strand breaks. Additionally, SG-55 can overcome resistance to Osimertinib mediated by the EGFRC797S triple mutation in non-small cell lung cancer (NSCLC).

AG 555 (Tyrphostin B46) is an EGFR tyrosine kinase inhibitor.

G-5555 hydrochloride is a potent and selective inhibitor of PAK1 [Ki: 3.7 nM].

Prezalumab (AMG 557) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF, used for studying Sjogren's syndrome, cutaneous lupus erythematosus, psoriasis, systemic lupus erythematosus arthritis, and systemic lupus erythematosus (SLE).

Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody that targets L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils. L-selectin plays a crucial role in directing cell migration through chemotaxis to injury sites. Aselizumab has been associated with an increased incidence of infections and leukopenia, particularly following trauma, suggesting potential safety concerns that need further investigation in clinical contexts.

Icenticaftor (QBW251) is an orally active potentiator of the CFTR channel.